Document:

ceoamendea.htm

     

    EXECUTION
COPY

     

    EMPLOYMENT
AGREEMENT

     

    THIS EMPLOYMENT AGREEMENT (the
“Agreement”) is made this 11th day of June, 2008 (the “Effective Date”) by
inVentiv Health, Inc., a Delaware corporation with its principal place of
business at 200 Cottontail Lane, Somerset, New Jersey 08873 (the “Company”), and
Eran Broshy, residing at 88 Central Park West, Apartment 1W, New York, NY 10023
(the “Executive”).

     

    WHEREAS, the parties wish to
set forth the terms and conditions upon which the Company will employ
Executive;

     

    NOW, THEREFORE, in consideration
of the mutual covenants and promises contained herein, and other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged by the parties hereto, the parties agree as follows:

     

    Section
1. Position;
Title; Duties.  Executive shall serve as Executive Chairman of
the Board of the Company and shall perform services consistent with that
position and as may be reasonably assigned to him from the Board of Directors of
the Company (the “Board”).

     

    Section
2. Extent of
Services. Executive agrees to
devote such portion of his business time and attention to the performance of his
duties under this Agreement as is consistent with the requirements of his
position or reasonably requested by the Board of Directors.  He shall
perform his duties to the best of his ability and shall use his best efforts to
further the interests of the Company.  Executive shall perform his
duties in the Company’s New York City and New Jersey metropolitan area offices
and will be required to travel as necessary to perform the services required of
him under this Agreement.  It is understood that Executive will
maintain his principal residence in New York City and it is anticipated that his
principal place of business will be in the New York – New Jersey metropolitan
area.

     

    Section
3. Compensation.  (a)  The
Company shall pay Executive an annual base salary of $300,000, subject to annual
review by the Board (it being understood that any determination the Board is
required or entitled to make hereunder, other than a determination pursuant to
Section 1 or 7(c), may be made by the Compensation Committee of the Board),
which may increase, but not decrease the amount thereof (the “Base
Salary”).  The Base Salary shall be payable in installments in
accordance with the Company’s ordinary payroll practices, minus such deductions
as may be required by law or reasonably requested by Executive.

     

    (b)  Executive shall be
eligible to receive option grants for the purchase of shares of the common stock
of the Company (“Options”) at the discretion of the Board; provided that no
Option shall have an exercise price less than the fair market value of the
common stock of the Company on the date of grant.  Under the
circumstances provided in Sections 7 through 9, all Options held by Executive
shall become fully vested.

     

    (c)  Executive shall be
eligible to receive grants of restricted shares of the common stock of the
Company (“Restricted Shares”) at the discretion of the Board.  Under
the circumstances provided in Sections 7 through 9, all restricted shares held
by Executive shall become fully vested.

     

    Section
4. Term of
Employment.  Executive is an employee “at will” and subject to
the provisions of Sections 7 through 9 hereof, Executive’s employment with the
Company may be terminated by the Company or by Executive at any time for any
reason.

     

    Section
5. Fringe
Benefits.  (a)  Benefits.  Executive
shall be entitled to all benefits generally available to senior executives of
the Company.

     

    (b)   Vacation.  Executive
shall be entitled to five (5) weeks of vacation during each year of
employment.  Executive shall be entitled to sick leave and holidays in
accordance with the policy of the Company applicable to its senior
executives.

     

    (c)   Car
Allowance.  Executive shall be entitled to monthly car
allowance $833.00, paid as taxable wages.  The allowance will end
effective with Executive’s termination.

     

    (d)           Life
Insurance.  The Company shall maintain for the benefit of
Executive during the term of his employment a minimum of $2.5 million in term
life insurance.

     

    Section
6. Reimbursement
of Business Expenses.  The Company shall reimburse Executive in
accordance with Company’s policies for all reasonable out-of-pocket costs
incurred or paid by Executive in connection with or related to, the performance
of his duties, responsibilities or services under this Agreement, upon
presentation by Executive of documentation, expense statements, vouchers, and/or
such other supporting information as the Company may reasonably
request.

     

    Section
7. Termination of Employment
Prior to a Change in Control.

     

    (a) Accrued
Amounts.  In the event of the termination of Executive’s
employment for any reason, Executive shall be entitled to (A) unpaid Base Salary
through the date of termination; (B) any benefits due to Executive under any
employee benefit plan of the Company and any payments due to Executive under the
terms of any Company program, arrangement or agreement, excluding any severance
program or policy and (C) any expenses owed to Executive ((A), (B) and (C)
collectively, the “Accrued Amounts”). Except as provided in Section 7(b),
Executive shall have no further right or entitlement under this Agreement upon a
termination of Executive’s employment within the scope of this Section
7.

     

    (b) Termination Without Cause;
For Good Reason. The Company may terminate Executive’s employment without
Cause (other than by reason of Disability) and Executive may terminate his
employment for Good Reason, in each case upon thirty (30) days prior written
notice (which, in the case of a termination of employment by Executive for Good
Reason, shall be given within ninety (90) days of the event or circumstance
constituting Good Reason).  In the event that the Company terminates
Executive’s employment without Cause (other than by reason of Disability) or
Executive terminates his employment for Good Reason, in either case prior to a
Change in Control, Executive shall be entitled to the following in lieu of any
payments or benefits under any severance program or policy of the
Company:

     

    (i)           the
Accrued Amounts;

    

    (ii)           a
lump sum cash severance payment, payable, subject to Section 20, within 10
business days of termination, equal to two times the Executive’s highest Base
Salary  (subsequent to the Effective Date) as of the date of
termination;

    

    (iii)           continued
coverage for a period of eighteen months commencing on the date of termination
under any Company life insurance plan in which Executive was participating
immediately prior to the date of termination;

    

    (iv)           the
health insurance benefits described below; and

    

    (v)           full
vesting of all Options, Stock Appreciation Rights and Restricted Shares
previously granted to Executive, which Options and Stock Appreciation Rights
shall remain exercisable for the period determined in accordance with Section
18.

    

    If and to
the extent the Company is not permitted under the terms of any applicable plan
or policy or applicable law to provide the benefits described in clause (iii)
above or Section 8(a)(iii) or 9(b)(iii) below, or if the provisions of such
benefits would cause any applicable plan to be deemed to be discriminating in
favor of highly compensated employees under the Employee Retirement Income
Security Act of 1974, as amended, the Company shall either (x) provide
equivalent benefits on an individual basis at no additional after-tax cost to
Executive (which may be accomplished by making payments to Executive sufficient
to pay, on an after-tax basis, the applicable portion of the premium cost under
the insurance policy(ies) maintained pursuant to Section 5(d) for the applicable
period following termination of Executive's employment with the Company) or (y)
pay to Executive an amount sufficient to permit Executive to purchase equivalent
benefits at no additional after-tax cost to Executive.

    

    If
Executive’s employment is terminated by the Company without Cause, if Executive
terminates his employment for Good Reason, if Executive's employment terminates
by reason of his death or if Executive is terminated for Disability (a
“Qualifying Termination”), then the Company shall continue health benefits to
Executive (and/or his spouse and eligible dependents, if any) equivalent to
those which would have been provided to them in accordance with the plans,
programs, practices and policies as made available to actively employed
executives of the Company (including, without limitation, co-pays, deductibles
and other required payments and limitations) as then in effect (or, if more
favorable, as in effect immediately prior to a Change in Control) (the “Welfare Plans”), for
a period of thirty-six months following such Qualifying Termination (the “Continuation
Period”).  If Executive does not make a timely election to
continue coverage under COBRA, the Continuation Period will be reduced by
eighteen (18) months.  If Executive is covered by health insurance of
a subsequent employer, the coverage provided under this Agreement will be
secondary to such other coverage.  Executive (or, where applicable,
his spouse and dependents) shall pay the full monthly premium cost of such
medical coverage for the Continuation Period.  The monthly premium
cost during the Continuation Period for Executive, spouse and dependents shall
be the monthly COBRA premium during the COBRA health care continuation coverage
period under section 4980B of the Code or, to the extent the COBRA coverage is
not in effect, such amount as is equal to the Company’s deemed cost of such
medical coverage for Executive and and/or his spouse and eligible dependents, if
any, which shall be determined actuarially by the Company’s advisors (the “Applicable
Premium”).  During the Continuation Period, the Company shall
pay Executive (or, where applicable, Executive’s spouse) an amount equal to the
135% of the Applicable Premium described above (the “Advance Premium”), as
in effect from time to time, which, subject to Section 13(d), shall be made in
advance on the first business day of each month, commencing with the month
immediately following Executive’s date of termination, provided that, subject to
Section 13(d), the first such payment shall be made within thirty (30) days
after Executive’s termination date.  The Company shall have no further
obligation to pay the Advance Premium after the earlier of: (A) Executive (or,
where applicable, his spouse and dependents) ceasing to participate in the
Welfare Plans and (B) the end of the Continuation Period.

     

     

    (c) Definition of
“Cause”.  For purposes of this Agreement, the term “Cause”
shall mean (i) Executive’s willful and continuing failure (except where due to
physical or mental incapacity) to substantially perform his duties hereunder or
refusal or failure to follow the lawful directives of the Board, in either case
which is not remedied within 15 days  after receipt of written notice
from the Company specifying such failure; (ii) Executive’s willful malfeasance
or gross neglect in the performance of his duties hereunder resulting in
material harm to the Company; (iii) Executive’s conviction of, or plea of guilty
or nolo
contendere to, a felony or a misdemeanor involving moral turpitude; (iv)
the commission by Executive of an act of fraud or embezzlement against the
Company or any affiliate; or (v) Executive’s willful material breach of any
material provision of this Agreement (as determined in good faith by the Board)
which is not remedied within 15 days after receipt of written notice from the
Company specifying such breach, provided that Executive shall be given the
opportunity to appear before the Board prior to the time such termination would
otherwise become effective.  For purposes of the preceding sentence,
no act or failure to act by Executive shall be considered “willful” unless done
or omitted to be done by Executive in bad faith or without reasonable belief
that Executive’s action or omission was in the best interests of the
Company.

     

    (d) Definition of “Good
Reason”.  For purposes of this Agreement, the term “Good
Reason” shall mean the occurrence, without Executive’s express written consent,
of: (i) any adverse change in Executive’s title agreed to or effected by the
Board, (ii) any material diminution in Executive’s employment duties,
responsibilities or authority, or the assignment to Executive of duties that are
materially inconsistent with his position, that is not cured within 15 days
after written notice thereof is received from Executive; (iii) any reduction in
Base Salary; (iv) a relocation of Executive’s principal place of employment to a
location inconsistent with Section 2 hereof that would unreasonably increase
Executive’s commute; (v) during Executive’s employment with the Company, any
failure of Executive to be nominated for election as a director of the Company
or the removal of Executive as a director of the Company by the Board other than
for cause; (vi) any willful material breach by the Company of any material
provision of this Agreement that is not cured within 15 days after written
notice thereof is received from Executive; or (vii) any termination of
employment by Executive during the thirty day period following the one year
anniversary of a Change in Control.  Each of Executive's Option and
Restricted Share awards shall provide (and if outstanding are hereby amended to
provide) that such awards shall accelerate upon an event described in clause (v)
that occurs following a termination of Executive's employment (other than a
termination for Cause).

     

    (e) In order
to be eligible to receive any Severance Payment pursuant to Section 7(b) hereof,
Executive must sign, prior to receiving such payment, a complete release of all
claims against Company (other than claims under this Section 7), in
substantially the form attached hereto as Exhibit I and such release must have
become effective in accordance with its terms.

     

    Section
8. Disability;
Death.

     

    (a) Termination Upon
Disability.  The Company may terminate Executive’s employment
by reason of Disability upon thirty (30) days prior written
notice.  If Executive is terminated for Disability, Executive shall be
entitled to the following in lieu of any payments or benefits under any
severance program or policy of the Company (but not in lieu of any disability
benefits to which Executive is entitled under any disability program or policy
of the Company):

     

    (i)           the
Accrued Amounts;

    

    (ii)           a
lump sum cash severance payment, payable, subject to Section 18, within 10
business days of termination, equal to two times the Executive’s highest Base
Salary (subsequent to the Effective Date) as of the date of termination, reduced
by any amount previously paid to the Executive pursuant to Section
9(a);

    

    (iii)           continued
coverage for a period of eighteen months commencing on the date of termination
under any Company life insurance plan in which Executive was participating
immediately prior to the date of termination;

    

    (iv)           the
health insurance benefits described in Section 7(b); and

    

    (v)           full
vesting of all Options, Stock Appreciation Rights and Restricted Shares
previously granted to Executive, which Options and Stock Appreciation Rights
shall remain exercisable for the period determined in accordance with Section
18.

    

    (b)           Definition of
Disability.  For purposes hereof, "Disability" means
Executive's inability due to physical or mental incapacity to perform the duties
and services of his position for a period of 120 days.  At the
Company's option, such physical or mental incapacity may be determined by a
physician selected by the Company and reasonably acceptable to Executive or
presumed by the Company on the basis of Executive's failure to perform the
duties and services of his position for a period of 120 days.

    

    (c)           Release.  In
order to be eligible to receive any payment pursuant to Section 8(a) hereof,
Executive must sign, prior to receiving such payment, a complete release of all
claims against Company (other than claims under this Section 10), in
substantially the form attached hereto as Exhibit I and such release must have
become effective in accordance with its terms.

    

    (d)           Death.  If
Executive dies during the term of his employment with the Company, (i)
Executive's estate shall be entitled to the Accrued Amounts and any death
benefits to which Executive is entitled under any program or policy of the
Company providing such benefits, and the Company shall have no other liability
to Executive's estate in respect of any additional compensatory or severance
amount, (ii) Executive's spouse and eligible dependents, if any shall be
entitled to the health insurance benefits described in Section 7(b) and (iii)
all Options, Stock Appreciation Rights and Restricted Shares previously granted
to Executive shall immediately vest in full and shall remain exercisable for the
period determined in accordance with Section 18.

     

    Section
9. Change in
Control.

     

    (a) Payment Upon Change in
Control.  In the event of a Change in Control while Executive
is employed by the Company, Executive shall be entitled to the
following:

    

    (i)           a
lump sum cash payment, payable, subject to Section 18, within 10 business days
of the Change in Control, equal to two times the Executive’s highest Base Salary
(subsequent to the Effective Date) as of the date of the Change in
Control;

    

    (ii)           full
vesting of all Options, Stock Appreciation Rights and Restricted Shares
previously granted to Executive, which Options and Stock Appreciation Rights
shall remain exercisable for the period determined in accordance with Section
18; and

     

    (iii)           any
Gross-Up Payment due in accordance with Section 9(c) hereof.

     

    (b) Termination Without Cause;
For Good Reason.  In the event that the Company terminates
Executive’s employment other than for Cause or Executive terminates his
employment for Good Reason within 13 months following a Change in Control,
Executive shall be entitled to the following in lieu of any payments or benefits
under any severance program or policy of the Company:

     

    (i)           the
Accrued Amounts;

    

    (ii)           a
lump sum cash severance payment, payable, subject to Section 18, within 10
business days of termination, equal to the Executive’s highest Base Salary
(subsequent to the Effective Date) as of the date of the Change in
Control;

    

    (iii)           continued
coverage for a period of thirty-six months commencing on the date of termination
under any Company life insurance plan in which Executive was participating
immediately prior to the date of termination;

    

    (iv)           the
health insurance benefits described in Section 7(b); and

     

    (v)           any
Gross-Up Payment due in accordance with Section 9(c) hereof.

     

    (c) Gross-Up
Payment.  (i)                                                      Anything
in this Agreement to the contrary notwithstanding, in the event it shall be
determined that any payment, award, benefit or distribution (or any acceleration
of any payment, award, benefit or distribution) by the Company (or any of its
affiliated entities) or any entity which effectuates a Change in Control to or
for the benefit of Executive (whether pursuant to the terms of this Agreement or
otherwise, but determined without regard to any additional payments required
under this Section 5(c)) (the “Payments”) would be subject to the excise tax
imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the
“Code”), or any interest or penalties are incurred by Executive with respect to
such excise tax (such excise tax, together with any such interest and penalties,
are hereinafter collectively referred to as the “Excise Tax”), then the Company
shall pay to Executive an additional payment (a “Gross-Up Payment”) in an amount
such that after payment by Executive of all taxes (including any Excise Tax)
imposed upon the Gross-Up Payment, Executive retains an amount of the Gross-Up
Payment equal to the sum of (x) the Excise Tax imposed upon the Payments and (y)
the product of any deductions disallowed because of the inclusion of the
Gross-Up Payment in Executive’s adjusted gross income and the highest applicable
marginal rate of federal income taxation for the calendar year in which the
Gross-Up Payment is to be made.  For purposes of determining the
amount of the Gross-Up Payment, Executive shall be deemed to (i) pay
federal income taxes at the highest marginal rates of federal income taxation
for the calendar year in which the Gross-Up Payment is to be made, (ii) pay
applicable state and local income taxes at the highest marginal rate of taxation
for the calendar year in which the Gross-Up Payment is to be made, net of the
maximum reduction in federal income taxes which could be obtained from deduction
of such state and local taxes and (iii) have otherwise allowable deductions
for federal income tax purposes at least equal to those which could be
disallowed because of the inclusion of the Gross-Up Payment in Executive’s
adjusted gross income.

     

    (ii)           Notwithstanding
the foregoing provisions of this Section 9(c), if it shall be determined that
Executive is entitled to the Gross-Up Payment, but that the Parachute Value of
all Payments does not exceed the Safe Harbor Amount by the lesser of (A) 5% of
the Safe Harbor Amount and (B) $50,000, then no Gross-Up Payment shall be made
to Executive and the amounts payable under this Agreement shall be reduced so
that the Parachute Value of all Payments, in the aggregate, equals the Safe
Harbor Amount; provided, however, that in no event, shall such reduction exceed
$50,000.  The reduction of the amounts payable hereunder, if
applicable, shall be made by reducing the payments and benefits under the
following sections in the following order: (i) the accelerated vesting of equity
pursuant to Section 9(a)(ii), (ii) the cash payment under Section 9(b) and (iii)
the cash payment under Section 9(a)(i).  For purposes of reducing the
Payments to the Safe Harbor Amount, only amounts payable under this Agreement
(and no other Payments) shall be reduced.  If the reduction of the
amounts payable under this Agreement in accordance with this Section 9(c)(ii)
would not result in a reduction of the Parachute Value of all Payments to the
Safe Harbor Amount, no amounts payable under the Agreement shall be reduced
pursuant to this Section 9(c).  The Company’s obligation to make
Gross-Up Payments under this Section 9(c) shall not be conditioned upon
Executive’s termination of employment.

     

    (iii)           Subject
to the provisions of Section 9(c)(i), all determinations required to be made
under this Section 9(c), including whether and when a Gross-Up Payment is
required, the amount of such Gross-Up Payment and the assumptions to be utilized
in arriving at such determinations, shall be made by PriceWaterhouse Coopers
(the “Accounting Firm”) which shall provide detailed supporting calculations
both to the Company and Executive within fifteen (15) business days of the
receipt of notice from the Company or Executive that there has been a Payment,
or such earlier time as is requested by Executive or the Company (collectively,
the “Determination”).  In the event that the Accounting Firm is
serving as accountant or auditor for the individual, entity or group effecting
the Change in Control, the Company and Executive shall jointly appoint another
nationally recognized public accounting firm to make the determinations required
hereunder (which accounting firm shall then be referred to as the Accounting
Firm hereunder).  All fees and expenses of the Accounting Firm shall
be borne solely by the Company and the Company shall enter into any agreement
requested by the Accounting Firm in connection with the performance of the
services hereunder.  The Gross-Up Payment under this Section 9(c) with
respect to any Payments shall be made no later than thirty (30) days following
such Payment.  The Determination by the Accounting Firm shall be
binding upon the Company and Executive.  As a result of the
uncertainty in the application of Section 4999 of the Code at the time of the
Determination, it is possible that Gross-Up Payments which will not have been
made by the Company should have been made (“Underpayment”) or Gross-Up Payments
are made by the Company which should not have been made (“Overpayment”),
consistent with the calculations required to be made hereunder.  In
the event that Executive thereafter is required to make payment of any Excise
Tax or additional Excise Tax, the Accounting Firm shall determine the amount of
the Underpayment that has occurred and any such Underpayment (together with
interest at the rate provided in Section 1274(b)(2)(B) of the Code) shall be
promptly paid by the Company to or for the benefit of Executive.  In
the event the amount of the Gross-Up Payment exceeds the amount necessary to
reimburse Executive for his Excise Tax, the Accounting Firm shall determine the
amount of the Overpayment that has been made and any such Overpayment (together
with interest at the rate provided in Section 1274(b)(2)(B) of the Code)
shall be promptly paid by Executive (to the extent he has received a refund if
the applicable Excise Tax has been paid to the Internal Revenue Service) to or
for the benefit of the Company.  Executive shall cooperate, to the
extent his expenses are reimbursed by the Company, with any reasonable requests
by the Company in connection with any contests or disputes with the Internal
Revenue Service in connection with the Excise Tax; provided that (i) the Company
shall bear and pay directly all legal and other costs and expenses of
Executive's representation in connection with such contest or dispute and (ii)
the Company shall indemnify and hold Executive harmless on the terms provided
above for any additional Excise Tax (including interest and penalties) imposed
as a result of such contest or dispute.

    

    (v)           The
following terms shall have the following meanings for purposes of this Section
9(c).

     

    
      	
              (A)  

            	
               “Parachute
      Value” of a Payment shall mean the value of such Payment the date of the
      change of control for purposes of Section 280G of the Code of the portion
      of such Payment that constitutes a “parachute payment” under Section
      280G(b)(2), as determined by the Accounting Firm for purposes of
      determining whether and to what extent the Excise Tax will apply to such
      Payment.

            

    

     

    
      	
              (B)  

            	
              The
      “Safe Harbor Amount” means 2.99 times Executive’s “base amount,” within
      the meaning of Section 280G(b)(3) of the
Code.

            

    

     

     

    (d) Definition of "Change in
Control".  For purposes of this Agreement, “Change in Control”
means

     

    

    
      	
               
      

            	
              (i)

            	
              The
      acquisition by any individual, entity or group (within the meaning of
      Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934,
      as amended (the “Exchange Act”))
      (a “Person”) of
      beneficial ownership (within the meaning of Rule 13d-3 promulgated under
      the Exchange Act) of more than 50% of either (A) the then-outstanding
      shares of common stock of the Company (the “Outstanding Company
      Common Stock”) or (B) the combined voting power of the
      then-outstanding voting securities of the Company entitled to vote
      generally in the election of directors (the “Outstanding Company
      Voting Securities”); provided, however, that,
      for purposes of this Section 9(d)(1), the following acquisitions
      shall not constitute a Change in Control: (i) any acquisition
      directly from the Company, (ii) any acquisition by the Company or
      (iii) any acquisition by any employee benefit plan (or related trust)
      sponsored or maintained by the Company or any Affiliated
      Company;

            

    

    

    
      	
               
      

            	
              (ii)

            	
              Individuals
      who, as of the Effective Date, constituted the Board (the “Incumbent
      Board”) cease for any reason to constitute at least a majority of
      the Board; provided, however, that
      any individual becoming a director subsequent to the Effective Date whose
      election, or nomination for election by the Company’s stockholders, was
      approved by a vote of at least a majority of the directors then comprising
      the Incumbent Board shall be considered as though such individual were a
      member of the Incumbent Board, but excluding, for this purpose, any such
      individual whose initial assumption of office occurs as a result of an
      actual or threatened election contest with respect to the election or
      removal of directors or other actual or threatened solicitation of proxies
      or consents by or on behalf of a Person other than the
    Board;

            

    

    

    
      	
               
      

            	
              (iii)

            	
              Consummation
      of a reorganization, merger, consolidation or sale or other disposition of
      all or substantially all of the assets of the Company (a “Business
      Combination”), in each case, unless, following such Business
      Combination, (A) all or substantially all of the individuals and
      entities that were the beneficial owners of the Outstanding Company Common
      Stock and the Outstanding Company Voting Securities immediately prior to
      such Business Combination beneficially own, directly or indirectly, more
      than 50% of the then-outstanding shares of common stock and the combined
      voting power of the then-outstanding voting securities entitled to vote
      generally in the election of directors, as the case may be, of the
      corporation resulting from such Business Combination (including, without
      limitation, a corporation that, as a result of such transaction, owns the
      Company or all or substantially all of the Company’s assets either
      directly or through one or more subsidiaries) in substantially the same
      proportions as their ownership immediately prior to such Business
      Combination of the Outstanding Company Common Stock and the Outstanding
      Company Voting Securities, as the case may be and (B) at least a
      majority of the members of the board of directors of the corporation
      resulting from such Business Combination were members of the Incumbent
      Board at the time of the execution of the initial agreement or of the
      action of the Board providing for such Business Combination;
      or

            

    

    

    
      	
               
      

            	
              (iv)

            	
              Approval
      by the stockholders of the Company of a complete liquidation or
      dissolution of the Company.

            

    

    

    (e)           Release.  In
order to be eligible to receive any payment pursuant to Section 9(b) or, with
respect to Section 9(b), Section 9(c) hereof, Executive must sign, prior to
receiving such payment, a complete release of all claims against Company (other
than claims under this Section 9), in substantially the form attached hereto as
Exhibit I and such release must have become effective in accordance with its
terms.

     

    Section
10. Non-Solicitation
and Non-Competition.  (a)  Except as provided in
paragraph (f) below, Executive agrees that while Executive is employed
pursuant to this Agreement and for a period of twelve (12) months following
termination of Executive’s employment by the Company for any reason (the
“Non-Competition Period”), whether by action of Executive or the Company,
Executive will not, except as otherwise provided herein, engage or participate,
directly or indirectly as principal, agent, executive, employer, consultant,
stockholder, partner or in any other individual capacity whatsoever, in the
conduct or management of, or own any stock or any other equity investment in or
debt of, any business which is competitive with any business conducted by the
Company.

     

    (b) For the
purpose of this Agreement, a business shall be considered to be competitive with
the business of the Company if such business is engaged in providing outsourced
commercialization services to the pharmaceutical industry or any other business
in which the Company is engaged at the time of termination of Executive’s
employment; provided that a pharmaceutical company shall not be deemed to be
competitive if the services Executive renders to such a company do not involve
providing outsourced commercialization services or any other business in which
the Company is engaged at the time of termination of Executive’s
employment.

     

    (c) During
the Non-Competition Period, Executive will not, for his own benefit or for the
benefit of any person or entity other than the Company, (i) solicit, or
assist any person or entity other than the Company to solicit any officer,
director, executive or employee of the Company to leave his/her employment,
(ii) hire or cause to be hired for Executive’s benefit any present or
former officer, director, executive or employee of the Company, or
(iii) engage any present or former officer, director, executive or employee
of the Company as a partner, contractor, sub-contractor, employee, consultant or
other business associate of Executive.

     

    (d) During
the Non-Competition Period, Executive will not (i) solicit, or assist any
person or entity other than the Company to solicit, any person or entity that is
a client of the Company, or has been a client of the Company during the twelve
(12) months prior to the date of termination of Executive’s employment, to
purchase outsourced commercialization services or any other products or services
the Company provides to a client, or (ii) interfere with any of Company’s
business relationships.

     

    (e) Executive
acknowledges that (i) the markets served by the Company are national in
scope and are not dependent on the geographic location of the executive
personnel or the businesses by which they are employed, and (ii) the above
covenants are manifestly reasonable on their face, and the parties expressly
agree that such restrictions have been designed to be reasonable and no greater
than is required for the protection of the Company.

     

    (f) Nothing
in this Agreement shall he deemed to prohibit Executive from owning equity or
debt investments in any corporation, partnership or other entity which is
competitive with the Company, provided that such
investments (i) are passive investments and constitute one percent (1%) or
less of the outstanding equity securities of such an entity the equity
securities of which are traded on a national securities exchange or other public
market and (ii) are approved by the Company.

     

    (g) The
parties to this Agreement mutually agree that, in recognition of Company’s
dependence on Executive’s experience to carry out its business plan and
Executive’s senior and key position in the Company, the restrictions detailed in
this Section 10 are necessary and appropriate to give effect to the
intended relationships of the parties.  Executive agrees that because
damages arising from violations of this Section 10 are extremely difficult
to quantify with certainty, injunctive relief will be necessary to effect the
intent of such Section.  Accordingly, Executive hereby consents to the
imposition of a preliminary or permanent injunction as a remedy to this breach
of this Section 10.

     

    (h) It is the
desire and intent of the parties hereto that the restrictions set forth in this
Section 10 shall be enforced and adhered to in every particular, and in the
event that any provision, clause or phrase shall be declared by a court of
competent jurisdiction to be judicially unenforceable either in whole or in part
– whether the limit be in duration, geographic coverage or scope of activities
precluded – the parties agree that they will mutually petition the court to
sever or limit the unenforceable provisions so as to retain and effectuate to
the greatest extent legally permissible the intent of the parties as expressed
in this Section 10.

     

    (i) For
purposes of Sections 10 and 11 of this Agreement, the “Company” shall be deemed
to refer to the Company and each of its subsidiaries.

     

    Section
11. Confidential
Information

     

    .  (a)  Executive
shall not (for his own benefit or the benefit of any person or entity other than
the Company) use or disclose any of the Company’s trade secrets or other
confidential information.  The term “trade secrets or other
confidential information” includes, by way of example, matters of a technical
nature, “know-how”, computer programs (including documentation of such
programs), research projects, and matters of a business nature, such as
proprietary information about costs, profits, markets, sales, lists of
customers, and other information of a similar nature to the extent not available
to the public, and plans for future development.  After termination of
this Agreement, Executive shall not use or disclose trade secrets or other
confidential information unless such information becomes a part of the public
domain other than through a breach of this Agreement or is disclosed to
Executive by a third party who is entitled to receive and disclose such
information.

     

    (b) Upon the
effective date of notice of Executive’s or the Company’s election to terminate
this Agreement, or at any time upon the request of the Company, Executive (or
his heirs or personal representatives) shall deliver to the Company all
documents and materials containing either trade secrets and confidential
information relating to the Company’s business or privileged information, and
all documents, materials and other property belonging to the Company, which in
either case are in the possession or under the control of Executive (or his
heirs or personal representatives).

     

    (c) All
discoveries and works made or conceived by Executive during his employment by
the Company, jointly or with others, that relate to the Company’s activities
shall be owned by the Company.  The terms “discoveries and works”
include, by way of example, inventions, computer programs (including
documentation of such programs), technical improvements, processes, drawings,
and works of authorship, including sales materials which relate to wall media
products, sampling/comparing or services.  Executive shall promptly
notify and make full disclosure to, and execute and deliver any documents
requested by, the Company to evidence or better assure title to such discoveries
and works by the Company, assist the Company in obtaining or maintaining for
itself at its own expense United States and foreign patents, copyrights, trade
secret protection and other protection of any and all such discoveries and
works, and promptly execute, whether during his employment or thereafter, all
applications or other endorsements necessary or appropriate to maintain patents
and other rights for the Company and to protect its title
thereto.  Any discoveries and works which, within six (6) months after
the termination of Executive’s employment by the Company, are made, disclosed,
reduced to a tangible or written form or description, or are reduced to practice
by Executive and which pertain to work performed by Executive while with the
Company shall, as between Executive and the Company, be presumed to have been
made during Executive’s employment by the Company

     

    Section
12. Enforcement.  Executive
agrees that the Company’s remedies at law for any breach or threat of breach by
him of the provisions of Sections 10 and 11 hereof will be inadequate, and that
the Company shall be entitled to an injunction or injunctions to prevent
breaches of the provisions of Sections 10 and 11 hereof and to enforce
specifically the terms and provisions thereof, in addition to any other remedy
to which the Company may be entitled at law or equity.

     

    Section
13. Indemnification.  The Company shall
indemnify Executive against any and all losses, liabilities, damages, expenses
(including attorneys’ fees) judgments, fines and amounts paid in settlement
incurred by Executive in connection with any claim, action, suit or proceeding
(whether civil, criminal, administrative or investigative), including any action
by or in the right of the Company, by reason of any act or omission to act in
connection with the performance of his duties hereunder to the full extent that
the Company is permitted to indemnify a director, officer, employee or agent
against the foregoing under applicable law.  The Company shall at all
times cause Executive to be included, in his capacity hereunder, under all
liability insurance coverage (or similar insurance coverage) maintained by any
of the Company from time to time.

     

    Section
14. Attorney’s
Fees and Costs.  In the event Executive institutes any action
to enforce his rights under this Agreement and prevails on at least one material
claim in such action, the Company shall pay Executive’s reasonable cost and
expenses (including legal fees) incurred in connection with such
action.

     

    Section
15. Tax
Withholding.  Notwithstanding
any other provision of this Agreement, the Company may withhold from amounts
payable under this Agreement all Federal, state, local and foreign taxes that
are required to be withheld by applicable laws or regulations.

     

    Section
16. No
Waiver.  Executive’s or
the Company’s failure to insist upon strict compliance with any provision of, or
to assert any right under, this Agreement shall not be deemed to be a waiver of
such provision or right or of any other provision of or right under this
Agreement.  Any provision of this Agreement may be waived by either
party; provided
that any waiver by any person of any provision of this Agreement shall be
effective only if in writing and signed by the person against whom enforcement
of the waiver is sought and such waiver must specifically refer to this
Agreement and to the terms or provisions being modified or waived.

     

    Section
17. No
Mitigation.  In no event shall
Executive be obligated to seek other employment or take other action by way of
mitigation of the amounts payable to Executive under any of the provisions of
this Agreement and such amounts shall not be subject to offset or otherwise
reduced whether or not Executive obtains other employment.  The
Company’s obligation to make any payment pursuant to, and otherwise to perform
its obligations under, this Agreement shall not be affected by any offset,
counterclaim or other right that the Company may have against Executive for any
reason.

     

    Section
18. Section
409A.   The parties
acknowledge and agree that, to the extent applicable, this Agreement shall be
interpreted in accordance with Section 409A of the Internal Revenue Code and the
Department of Treasury Regulations and other interpretive guidance issued
thereunder, including without limitation any such regulations or other guidance
that may be issued after the Effective Date (“Section 409A”).  The
Company shall take, and Executive shall cooperate with the Company in taking,
all steps reasonably necessary to have such benefits not be deferred
compensation arrangements under Section 409A, including adopting such amendments
to this Agreement and appropriate policies and procedures, including amendments
and policies with retroactive effect, that are reasonably necessary or
appropriate to preserve the intended tax treatment of the benefits provided by
this Agreement, provided that (i) the Company will not be required to take any
such steps that impose any material additional costs on the Company and shall
not take any such steps that impose any material additional costs on Executive
(unless Executive otherwise consents thereto) and (ii) the Company will not be
liable for the failure to take any such steps or for the imposition of any tax
or penalty pursuant to Section 409A.

     

    Without limitation of the preceding
paragraph, the parties agree that:

     

    (i)  With
respect to the time period within which Executive may exercise any outstanding
stock options or stock appreciation rights, the parties agree to avoid the
imposition of Section 409A, Executive shall be entitled to exercise such options
and rights through the earliest of (i) the maximum date that is permitted under
Section 409A, (ii) the second anniversary of the date of Executive’s termination
or death or Disability, as applicable (or any longer period during which
executive officers generally are permitted to exercise stock options or stock
appreciation rights under such circumstances) and (iii) if Executive's
employment is terminated by the Company for Cause or by Executive other than for
Good Reason (and not by reason of death or Disability), Executive shall be
entitled to exercise such options and rights through such date as is prescribed
under the applicable incentive plan and grant documentation, and further
provided that in no event will the option or stock appreciation right remain
exercisable beyond its original term.

     

    (ii)  For
purposes of Section 9(c) and Section 14 of this Agreement, the Company shall pay
the fees and expenses of the Accounting Firm and/or the legal fees and expense
incurred as a result of any contest under Section 14 not later than the end of
the calendar year following the calendar year in which the related work is
performed or the expenses are incurred by the Accounting Firm or Executive, as
applicable, and the Company shall pay all other amounts that it is required to
pay to or on behalf of Executive under Section 9(c) of this Agreement not later
than the end of the calendar year following the calendar year in which the
related Taxes are remitted to the applicable taxing authority.  The
amount of such fees and expenses that the Company is obligated to pay in any
given calendar year shall not affect the legal fees and expenses that the
Company is obligated to pay in any other calendar year, and Executive’s right to
have the Company pay such legal fees and expenses may not be liquidated or
exchanged for any other benefit.

     

    (iii)  Subject
to paragraph (iv) below, except as otherwise provided herein, each lump sum
payment that is to be made pursuant to this Agreement, other than the payments
described in Sections 7(b) and 8(a) of this Agreement, shall be made not later
than ninety (90) days following the date of the event giving rise to such lump
sum cash payment.

     

    (iv)  If
Executive is a “specified employee,” defined under Section 409A and as
determined by the Company in good faith in accordance with the Company’s
policies, on the date of his termination from employment with the Company, to
the extent required in order to comply with Section 409A, cash amounts to be
paid under Sections 7, 8 and 9 of this Agreement on account of Executive’s
termination of employment for any reason other than death (other than Accrued
Amounts) and any other amounts deemed to be “nonqualified deferred compensation”
under Section 409A shall be paid to Executive on the earlier of (i) the first
business day after the date that is six (6) months following Executive’s
“separation from service” within the meaning of Section 409A and (ii)
Executive’s death subsequent to Executive’s termination of employment for any
reason other than death, in each case, with interest from the date on which
payment would otherwise have been made, calculated at the applicable federal
rate provided under Section 7872(f)(2)(A) of the Code (“Interest”).

     

    (v)  Any
Gross-Up Payment described in Section 9(c) and any payments or reimbursements of
life or health insurance expenses pursuant to Section 7(b) shall be made by the
end of the calendar year next following the calendar year in which the related
taxes are remitted to the taxing authority by Executive.

     

    (vi)  Any
payment to be made pursuant to Section 9(a) of this Agreement shall be made upon
the Change in Control but in no event later than two and one-half (2 1⁄2) months
following the year in which the Change in Control occurred.

     

    (vii)  Each
of the payments described in this Agreement shall be classified as a “separate
payment” under Section 409A. As used in this Agreement, a “termination of
employment” (or words of similar meaning) shall mean a “separation from service”
under Code Section 409A (and the Treasury Regulations promulgated thereunder)
and, subject to Section 13(d) of this Agreement, any benefit or amount to be
paid to, or with respect to, Executive, shall not be made until Executive has a
“separation from service” within the meaning of Section 409A of the
Code

     

    Section
19. Advance
Notice of Prospective Employment.  Executive agrees that
following the termination of his employment, prior to accepting employment with,
or agreeing to perform services for, any entity that competes with the Company,
he will notify the Company in writing of Executive’s intentions so as to provide
the Company with the opportunity to assess whether Executive’s employment or
retention may potentially violate any provisions of this Agreement.

     

    Section
20. Miscellaneous
Provisions.

     

    (a) Notices.  All
notices required or permitted under this Agreement shall be in writing and shall
be deemed effective upon personal delivery or upon deposit with (i) the United
States Postal Service, by registered or certified mail, postage prepaid, or (ii)
a reliable overnight courier service, addressed to the other party at the
address set forth above (in the case of the Company,
"Attention:  Chairman of the Compensation Committee").

     

    (b) Pronouns.  Whenever
the context may require, any pronouns used in this Agreement shall include the
corresponding masculine, feminine or neuter forms, and the singular forms of
nouns and pronouns shall include the plural, and vice versa.

     

    (c) Entire
Agreement.  This Agreement constitutes the entire agreement
between the parties and supersedes all prior agreements and understandings,
whether written or oral, relating to the subject matter of this Agreement,
including, but not limited to, the Employment Agreement dated as of May 9, 2006
between Executive and the Company, as heretofore
amended.  Notwithstanding the foregoing, all prior grant or award
agreements relating to stock options and restricted stock will remain in effect
except to the extent explicitly modified by this Agreement.

     

    (d) Amendment.  This
Agreement may be amended or modified only by a written instrument executed by
both the Company and Executive.

     

    (e) Governing
Law.  This Agreement shall be construed, interpreted and
enforced in accordance with the laws of the State of New York, without regard to
its conflict of law principles.

     

    (f) Successors and
Assigns.  This Agreement shall be binding upon and inure to the
benefit of both parties and their respective successors and assigns; provided, however, that the
obligations of Executive are personal and shall not be assigned or delegated by
him.

     

    (g) Waiver.  No
delays or omissions by the Company or Executive in exercising any right under
this Agreement shall operate as a waiver of that or any other
right.  A waiver or consent given by the Company or Executive on any
one occasion shall be effective only in that instance and shall not be construed
as a bar or waiver of any right on any other occasion.

     

    (h) Captions.  The
captions appearing in this Agreement are for the convenience of reference only
and in no way define, limit or affect the scope or substance of any section of
this Agreement.

     

    (i) Severability.  In
case any provision of this Agreement shall be held by a court with jurisdiction
over the parties to this Agreement to be invalid, illegal or otherwise
unenforceable, the validity, legality and enforceability of the remaining
provisions shall in no way be affected or impaired thereby.

     

    (j) Cooperation of the
Parties.  The Company and Executive agree to make all
reasonable efforts to cooperate to insure compliance with this
Agreement.

     

    (k) Duration of
Terms.  The respective rights and obligations of the parties
hereunder shall survive any termination of Executive’ employment, the Term or
this Agreement to the extent necessary to give effect to such rights and
obligations.

     

    (l) Counterparts.  This
Agreement may be executed simultaneously in two or more counterparts, each of
which shall be deemed an original but all of which together shall constitute one
and the same instrument.

    
      
        
           

        

         

      

      
         

        
          

        

      

      
         

      

    

     

    IN WITNESS WHEREOF, the
parties have executed this Agreement as of the day and year first written
above.

    
      	
              COMPANY

              inVentiv
      Health, Inc.

            	
              EXECUTIVE

            
	
               

              By:
      /s/ Per G.H. Lofberg

              Name:  Per
      G.H. Lofberg

                    Member,
      Compensation Committee of the Board of Directors

               

               

            	
               

              By:  /s/ Eran Broshy

              Name:  Eran
      Broshy

               

            
	
               

              By:  /s/ Mark Jennings

              Name:  Mark
      Jennings

                    Member,
      Compensation Committee of the Board of Directorsexhibit1032_csaolympus.htm

    Exhibit
10.32

     

    

      COMMON STOCK PURCHASE
AGREEMENT

       

      This
Common Stock Purchase Agreement (the “Agreement”) is made
as of August 1, 2008 (the “Effective Date”), by and between Cytori Therapeutics,
Inc., a Delaware corporation (the “Company”), and
Olympus Corporation, a Japan corporation with its principal executive office
located at  43-2 Hatagaya 2-chome, Shibuya-ku, Tokyo, Japan
(“Purchaser”)
(the Company and Purchaser are referred to collectively as the “Parties”).

       

      1.           Sale of
Stock.  Subject to the
terms and conditions of this Agreement, the Company will issue and sell to
Purchaser, and Purchaser agrees to purchase from the Company, [923,077]
unregistered shares of the Company’s Common Stock (the “Shares”) at a
purchase price of US$[6.50] per Share for a total of US $6,000,000 (the “Purchase Price”). The
Purchase Price per share shall be subject to any adjustment that is more
favorable to Purchaser in accordance with the terms of Section 13 of this
Agreement.

       

      2.           Closing.  The purchase and
sale of the Shares under Section 1 of this Agreement shall occur at the
principal office of the Company within seven (7) days of the Effective Date of
this Agreement (the “Closing”) at a date
and time agreed between the Parties.  At the Closing, Purchaser shall
deliver the Purchase Price to the Company by wire transfer, or by alternate
means agreed between the Parties, and the Company shall deliver a certificate
representing the Shares to Purchaser. 

       

      3.           Limitations
on Transfer.  Purchaser shall
not assign, encumber or dispose of any interest in the Shares except in
compliance with applicable securities laws and regulations of applicable
countries and stock exchanges.  It is Purchaser’s responsibility to
familiarize itself with such laws and regulations.

       

      4.           Company’s
Representations and Warranties. The Company represents and
warrants the following to Purchaser as of the Effective Date and as of the date
of the Closing:

      

      (a)           The
Company is duly organized, validly existing and in good standing under the laws
of the State of Delaware, with full corporate power and authority to conduct its
business as it is now being conducted to own or use the properties and assets
that it purports to own or use.  The Company is duly qualified to do
business as a foreign corporation and is in good standing under the laws of each
state or other jurisdiction in which either the ownership or use of the
properties owned or used by it, or the nature of the activities conducted by it,
requires such qualification.

      

      (b)           The
Company has the right and power to enter into and perform its obligations under
this Agreement and to consummate the transactions contemplated hereby; has taken
or will take prior to the Closing all necessary corporate actions required for
the Company to enter into and perform its obligations under this Agreement; and
this Agreement constitutes the legal, valid and binding obligation of the
Company, enforceable in accordance with its terms, except as enforcement may be
limited by general principles of equity whether applied in a court of law or a
court of equity and by bankruptcy, insolvency and similar laws affecting
creditors’ rights and remedies generally.

      

      (c)           The
execution of this Agreement and the consummation of the transactions
contemplated hereby will not result in a breach of any of the terms or
provisions of, or constitute a default under, the Company’s certificate of
incorporation or bylaws, as now in effect, or any agreement, or other instrument
to which the Company is a party or by which it is bound.

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

      

      (d)           The
sale and issuance of the Shares will not require any notice to, action of,
filing with or consent, authorization, order or approval from, any governmental
entity or other person that has not already been provided or obtained, as the
case may be.  Without limiting the foregoing, no action is required to
be taken by the Company to effect the sale and issuance of the Shares under any
state corporate or any other laws, rules or regulations that has not already
been taken.  The Company has not entered into any agreement to pay
commissions to any persons with respect to the purchase or sale of the Shares,
except commissions for which the Company will be responsible.

      

      (e)           The
authorized capital of the Company consists solely of 95,000,000 authorized
shares of common stock, and 5,000,000 shares of preferred stock.

      

      (f)           The
Shares, when issued, sold and delivered in accordance with the terms of this
Agreement for the Purchase Price, will be duly and validly issued, fully paid
and non-assessable, issued in compliance with all applicable federal, state and
foreign laws, free of any preemptive or similar rights that entitle or would
entitle any person to acquire any shares of capital stock of the Company upon
issuance thereof by the Company, and free and clear of all liens, mortgages,
security interests, encumbrances (other than applicable securities laws
restrictions), equities or claims.

      

      (g)            The Company has timely
filed all registration statements, prospectuses, forms, reports and documents
required to be filed by it under the Securities Act of 1933, as amended (the
“Securities
Act”), or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as
the case may be, since December 31, 2004 (each a “Company SEC Filing,”
and collectively the “Company SEC
Filings”).  Each Company SEC Filing (i) as of its date complied
in all material respects with the requirements of the Securities Act or the
Exchange Act, as the case may be, and (ii) did not, at the time it was filed,
contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements made
therein, in the light of the circumstances under which they were made, not
misleading.  Each of the consolidated financial statements (including,
in each case, any notes thereto) contained in the Company SEC Filings was
prepared in accordance with generally accepted accounting principles applied
(except as may be indicated in the notes thereto and, in the case of unaudited
quarterly financial statements, as permitted by Form 10-Q under the Exchange
Act) on a consistent basis throughout the periods indicated (except as may be
indicated in the notes thereto), and each presented fairly the consolidated
financial position of the Company as of the respective date thereof and for the
respective periods indicated therein (subject, in the case of unaudited
statements, to normal and recurring year-end adjustments.)  The books
and records of the Company have been, and are being, maintained in accordance
with applicable legal and accounting requirements.

      

      (h)           Except
as disclosed in the Company SEC Filings, since December 31, 2007, the Company
has conducted its business in the ordinary course, consistent with past
practice, and there has not been:

      

      (i)           any
event, occurrence or development which would, individually or in the aggregate,
reasonably be expected to have a material adverse effect on the Company or its
subsidiaries, taken as a whole, other than developments generally in the
industries in which the Company operates its business, provided that such
developments have not disproportionately affected the Company or any of its
subsidiaries individually or taken as a whole; or

      

      (ii)           any
event or development that would, individually or in the aggregate, reasonably be
expected to prevent or materially delay the performance of the Company of its
obligations hereunder.

       

      
        
          
          

        

        
          -2-

          
            

          

        

        
          
          

        

      

       

      5.           Investment
Representations and Warranties.  In connection
with the purchase of the Shares, Purchaser makes the following representations
and warranties to the Company as of the Effective Date and as of the date of the
Closing:

       

      (a)           This
Agreement has been duly authorized and executed by Purchaser and, when delivered
by Purchaser in accordance with its terms, will constitute the valid and legally
binding obligation of Purchaser, enforceable against it in accordance with its
terms, except as enforcement may be limited by general principles of equity
whether applied in a court of law or a court of equity and by bankruptcy,
insolvency and similar laws affecting creditors’ rights and remedies
generally.

       

      (b)           Purchaser
understands that the Company is a reporting company under the Exchange Act, and
the Company’s various periodic reports and other SEC filings are available for
public inspection on the EDGAR system at www.sec.gov.  Purchaser
further acknowledges that Purchaser and Purchaser’s advisors have had the
opportunity to ask questions of and receive answers from the Company’s
management concerning this investment.  Purchaser is aware of the
Company’s business affairs and financial condition based on the said public
available information and the answers from the Company’s management (the “Information”), and
Purchaser and Purchaser’s advisors have evaluated the merits and risks of an
investment in the Company and decided to acquire the Shares based on such
Information and on the Company’s representations and warranties set forth in
Section 4 above.

       

      (c)           Purchaser
understands that the Shares have not been registered under the U.S. Securities
Act by reason of a specific exemption therefrom, which exemption depends upon,
among other things, the bona fide nature of Purchaser’s investment intent as
expressed herein.

       

       (d)           Purchaser
understands that the Shares are “restricted securities” as defined in Rule 144
promulgated under the Securities Act and that, consequently, Purchaser must hold
the Shares indefinitely unless they are registered with the Securities and
Exchange Commission (the “Commission”) and
qualified by state authorities and resold pursuant to the requirements of such
registration/qualification, or an exemption from such registration and
qualification requirements is available.  Purchaser further
acknowledges that if an exemption from registration or qualification is
available, it may be conditioned on various requirements including, but not
limited to, the time and manner of sale, the holding period for the Shares, and
requirements relating to the Company which are outside of Purchaser’s control,
and which the Company is under no obligation and may not be able to
satisfy.

       

      (e)           Purchaser
is an “accredited investor,” as defined in Rule 501 promulgated under the
Securities Act.

       

      (f)           Purchaser
has not entered into any agreement to pay commissions to any persons with
respect to the purchase or sale of the Shares, except commissions for which
Purchaser will be responsible.

       

      (g)           Purchaser
understands and acknowledges that no Japanese or United States federal or state
agency, governmental authority, regulatory body, stock exchange or other entity
has made any finding or determination as to the merits of this investment, nor
have any such agencies, governmental authorities, regulatory bodies, stock
exchanges or other entities made any recommendation or endorsement with respect
to the Shares.

       

      
        
          
          

        

        
          -3-

          
            

          

        

        
          
          

        

      

       

      (h)           Purchaser,
in evaluating the merits of an investment in the Shares, is not relying on the
Company, its counsel, or any financial or other advisor to the Company for an
evaluation of the tax, legal or other consequences of an investment in the
Shares.

       

      (i)           Purchaser
is purchasing the Shares for investment for its own account only and not with a
view to, or for resale in connection with, any “distribution” thereof within the
meaning of Section 2(11) of the Securities Act.

       

      6.           Closing Conditions.

       

      (a)           Purchaser’s
obligation to consummate the transactions to be performed by it at the Closing
is subject to satisfaction of the following conditions:

       

      (i)           No
preliminary or permanent injunction or other binding order, decree or ruling
issued by a court or government authority shall be in effect which shall have
the effect of preventing the consummation of the transactions contemplated by
this Agreement;

       

      (ii)           The
representations and warranties of the Company contained in Section 4 hereof
shall be true and correct on and as of the Closing with the same effect as
though such representations and warranties had been made on and as of the
Closing;

       

      (iii)           The
Company shall have performed and complied in all material respects with all
agreements, obligations and conditions contained in this Agreement that are
required to be performed or complied with by it on or before the
Closing;

       

      (iv)           The
Company shall have obtained any and all consents, permits and waivers necessary
or appropriate for consummation of the sale of the Shares to Purchaser;
and

       

      (v)           The
Company shall have obtained all necessary permits and qualifications, if any, or
secured an exemption therefrom, required by any governmental authority prior to
the offer and sale of the Shares to Purchaser.

       

      (b)           The
Company’s obligation to consummate the transactions to be performed by it at the
Closing is subject to satisfaction of the following conditions:

       

      (i)           The
representations and warranties of Purchaser contained in Section 5 hereof shall
be true and correct on and as of the Closing with the same effect as though such
representations and warranties had been made on and as of the Closing;
and

       

      (ii)           Purchaser
shall have delivered the Purchase Price against delivery of the
Shares.

       

      7.           Legends.  The certificates
representing the Shares shall bear the following legends:

       

      “The
shares of common stock of Cytori Therapeutics, Inc. represented hereby have not
been registered under the United States Securities Act of 1933, as amended (the
“Securities Act”).  These securities may not be offered, sold, pledged
or otherwise transferred (nor may exposure with respect to the shares otherwise
be hedged) except (A)(1) pursuant to an effective registration statement under
the Securities Act, (2) pursuant to an exemption from registration under the
Securities Act provided by Rule 144 thereunder (if available), or (3) pursuant
to another valid exemption from registration under the 

       

      
        
          
          

        

        
          -4-

          
            

          

        

        
          
          

        

      

       

      Securities
Act (if available), and (B) in each case in accordance with all applicable
securities laws of the States of the United States.  No representation
is made hereby as to the availability of the exemption provided by Rule 144
under the Securities Act for resales of the shares.

       

      This
certificate evidences and entitles the holder hereof to certain rights as set
forth in a Rights Agreement between Cytori Therapeutics, Inc. and Computershare
Trust Company, Inc., a Colorado corporation, as Rights Agent, dated as of May
29, 2003, as amended (the “Rights Agreement”), the terms of which are hereby
incorporated herein by reference and a copy of which is on file at the principal
executive offices of Cytori Therapeutics, Inc. Under certain circumstances, as
set forth in the Rights Agreement, such rights will be evidenced by separate
certificates and will no longer be evidenced by this certificate. Cytori
Therapeutics, Inc. will mail to the holder of this certificate a copy of the
Rights Agreement without charge after receipt of a written request therefor.
Under certain circumstances set forth in the Rights Agreement, rights issued to,
or held by, any Person who is, was or becomes an Acquiring Person or an
Affiliate or Associate thereof (as such terms are defined in the Rights
Agreement) and certain related Persons, whether currently held by or on behalf
of such Person or by any subsequent holder, may become null and
void.”

       

      8.           Registration.  The
Company shall use reasonable efforts to prepare and file with the Commission
within 30 business days after receipt of written request by Purchaser a
Registration Statement covering the resale of the Shares for an offering to be
made on a continuous basis pursuant to Rule 415. The Registration Statement
shall be on Form S-3 (except if the Company is not then eligible to register for
resale the Shares on Form S-3, in which case such registration shall be on
another appropriate form in accordance with the Securities Act and the rules
promulgated thereunder).  The Company shall use reasonable efforts to
cause the Registration Statement to be declared effective under the Securities
Act as soon as practicable after its filing. The Company shall notify Purchaser
when the Registration Statement is available for offer and sale of the
Shares.  The Company shall keep such Registration Statement
continuously effective under the Securities Act for a period of two (2) years,
or until the date upon which all of the Shares may be sold pursuant to Rule 144
under the Securities Act, whichever occurs first (the “Effectiveness
Period”).

       

      9.           Registration
Procedures; Company’s Obligations.  In connection
with, and without limiting in any respect, the Company’s obligations for the
registration of the Shares above, the Company shall, as promptly as
possible: 

       

      (a)           Furnish
to Purchaser a copy of the Registration Statement as proposed to be
filed.

       

      (b)           (i)
Prepare and file with the Commission such amendments, including post-effective
amendments, to the Registration Statement as may be necessary to keep the
Registration Statement continuously effective as to the applicable Shares for
the Effectiveness Period; (ii) cause the related Prospectus to be amended or
supplemented by any required Prospectus supplement, and as so supplemented or
amended to be filed pursuant to Rule 424 (or any similar provisions then in
force) promulgated under the Securities Act; and (iii) respond to any comments
received from the Commission with respect to the Registration Statement or any
amendment thereto and provide Purchaser true and complete copies of all
correspondence from and to the Commission relating to the Registration
Statement.

      

      (c)           Notify
Purchaser (i)(A) when a Prospectus or any Prospectus supplement or
post-effective amendment to the Registration Statement is proposed to be filed,
(B) when the Commission notifies the Company whether there will be a “review” of
such Registration Statement and 

       

      
        
          
          

        

        
          -5-

          
            

          

        

        
          
          

        

      

       

      whenever
the Commission comments in writing on such Registration Statement, and (C) when
the Registration Statement or post-effective amendment, as the case may be, has
become effective; (ii) of any request by the Commission or any other federal or
state governmental authority for amendments or supplements to the Registration
Statement or Prospectus or for additional information; (iii) of the issuance by
the Commission of any stop order suspending the effectiveness of the
Registration Statement covering any or all of the Shares or the initiation of
any proceedings for that purpose; (iv) of the receipt by the Company of any
notification with respect to the suspension of the qualification or exemption
from qualification of any of the Shares for sale in any state of the U.S., or
the initiation or threatening of any proceeding for such purpose; and (v) of the
occurrence of any event that makes any statement made in the Registration
Statement or Prospectus or any document incorporated or deemed to be
incorporated therein by reference untrue in any material respect or that
requires any revisions to the Registration Statement, Prospectus or other
documents so that, in the case of the Registration Statement or the Prospectus,
as the case may be, it will not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to
make the statements therein, in the light of the circumstances under which they
were made, not misleading.

       

      (d)           Use
its reasonable commercial efforts to avoid the issuance of, or, if issued,
obtain the withdrawal of, (i) any order suspending the effectiveness of the
Registration Statement, or (ii) any suspension of the qualification (or
exemption from qualification) of any of the Shares for sale in any state of the
U.S.

       

      (e)           If
requested by Purchaser, (i) incorporate in a Prospectus supplement or
post-effective amendment to the Registration Statement such information as the
Company reasonably agrees should be included therein, and (ii) make all required
filings of such Prospectus supplement or such post-effective amendment after the
Company has received notification of the matters to be incorporated in such
Prospectus supplement or post-effective amendment.

       

      (f)           Furnish
to Purchaser, without charge, one copy of the Registration Statement and all
amendments thereto, and such number of copies of the Prospectus and all
amendments and supplements thereto and such other documents as Purchaser may
reasonably request in order to facilitate its disposition of
Shares.

       

      (g)           Use
its reasonable commercial efforts to register or qualify, and to cooperate with
Purchaser in connection with the registration or qualification (or exemption
from such registration or qualification) of, the Shares for offer and sale under
the securities or Blue Sky laws of each state of the U.S. as Purchaser
reasonably requests in writing, to keep each such registration or qualification
(or exemption therefrom) effective during the Effectiveness Period and to do any
and all other acts or things necessary or advisable to enable the disposition in
such states of the Shares covered by a Registration Statement; provided, however, that the
Company shall not be required to qualify generally to do business in any
jurisdiction where it is not then so qualified or to take any action that would
subject it to general service of process in any such jurisdiction where it is
not then so subject.

       

       (h)           Upon
the occurrence of any event contemplated by Section 9(c)(v) hereof, prepare a
supplement or amendment, including a post-effective amendment, to the
Registration Statement or a supplement to the related Prospectus or any document
incorporated or deemed to be incorporated therein by reference, and file any
other required document so that, as thereafter delivered, neither the
Registration Statement nor such Prospectus will contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.

       

      
        
          
          

        

        
          -6-

          
            

          

        

        
          
          

        

      

       

       (i)           Use
its reasonable efforts to cause all Shares to be listed on any U.S. national
securities exchange (such as the NASDAQ Global Market), U.S. quotation system,
or U.S. over-the-counter bulletin board, if any, on which the same securities
issued by the Company are then listed.

       

       (j)           If
(i) there is material non-public information regarding the Company which the
Company’s Board of Directors reasonably determines not to be in the Company’s
best interest to disclose and which the Company is not otherwise required to
disclose, or (ii) there is a significant business opportunity (including, but
not limited to, the acquisition or disposition of assets (other than in the
ordinary course of the Company’s business consistent with past practice) or any
merger, consolidation, tender offer or other similar transaction) available to
the Company which the Company’s Board of Directors reasonably determines in the
Company’s best interest should not be disclosed and which the Company would be
required to disclose under the Registration Statement, then the Company may
suspend effectiveness of the Registration Statement and suspend the sale of
Shares under the Registration Statement one time in any three-month period or
three times in any 12-month period upon written notice of such suspension to
Purchaser, provided that the Company may not suspend its obligations for more
than 60 days in the aggregate in any 12-month period.

       

      10.           Registration
Procedures; Purchaser’s Obligations.  In connection with the
registration of the Shares, Purchaser shall:

       

      (a)           (i)
not sell any Shares under the Registration Statement until Purchaser has
received copies of the Prospectus as then amended or supplemented and notice
from the Company that such Registration Statement and any post-effective
amendments thereto have become effective as contemplated by Section 9(c) hereof,
(ii) comply with any prospectus delivery requirements of the Securities Act as
applicable to Purchaser in connection with sales of Shares pursuant to the
Registration Statement, and (iii) furnish to the Company such information
regarding Purchaser and the distribution of the Shares as is required by law to
be disclosed in the Registration Statement.

      

       

      (b)           upon
receipt of a notice from the Company of the occurrence of any event of the kind
described in Section 9(c)(ii), 9(c)(iii), 9(c)(iv), 9(c)(v) or 9(j) hereof,
forthwith discontinue disposition of the Shares under the Registration Statement
until Purchaser’s receipt of the copies of the supplemented Prospectus and/or
amended Registration Statement contemplated by Section 9(i), or until it is
advised in writing by the Company that the use of the applicable Prospectus may
be resumed, and, in either case, has received copies of any additional or
supplemental filings that are incorporated or deemed to be incorporated by
reference in such Prospectus or Registration Statement.

       

      11.           Registration
Expenses.

      

      All fees
and expenses incident to the performance of or compliance with the obligations
under Section 9 of this Agreement, including, without limitation, registration
and filing fees, printing expenses, and fees and expenses of counsel and
independent public accountants for the Company, shall be borne by the Company
whether or not any Shares are sold pursuant to the Registration
Statement.

       

      12.           Indemnification.

       

      (a)           Indemnification by the
Company. The Company shall defend, indemnify and hold harmless Purchaser,
Purchaser’s permitted assignees, officers, directors, agents, brokers,
investment advisors and employees, each person who controls Purchaser or a
permitted assignee (within the meaning 

       

      
        
          
          

        

        
          -7-

          
            

          

        

        
          
          

        

      

       

      of
Section 15 of the Securities Act or Section 20 of the Exchange Act) and the
officers, directors, agents and employees of each such controlling person, and
the respective successors, heirs, assigns, estate and personal representatives
of each of the foregoing, to the fullest extent permitted by applicable law,
from and against any and all claims, losses, damages, liabilities, penalties,
judgments, costs (including, without limitation, costs of investigation) and
expenses (including, without limitation, reasonable attorneys’ fees and
expenses) (collectively, “Losses”), as
incurred, arising out of or relating to any breach by the Company of any of its
representations, warranties, covenants or agreements contained in or made
pursuant to this Agreement or arising out of or relating to any untrue or
alleged untrue statement of a material fact contained in the Registration
Statement or any Prospectus, each as supplemented or amended, if applicable, or
arising out of or relating to any omission or alleged omission of a material
fact required to be stated therein or necessary to make the statements therein
(in the case of any Prospectus or amendment or supplement thereto, in the light
of the circumstances under which they were made) not misleading, except (i) to
the extent, but only to the extent, that such untrue statements or omissions are
based solely upon information regarding Purchaser furnished in writing to the
Company by Purchaser expressly for use therein, or (ii) as a result of the
failure of Purchaser to deliver a Prospectus, as amended or supplemented, to a
purchaser in connection with an offer or sale. The Company shall notify
Purchaser in writing promptly of the institution, threat or assertion of any
Proceeding of which the Company is aware in connection with the transactions
contemplated by this Agreement and provide a reasonable description of such
institution, threat or assertion.  Such indemnity shall remain in full
force and effect regardless of any investigation made by or on behalf of an
Indemnified Party (as defined in Section 12(b) hereof) and shall survive the
transfer of the Shares by Purchaser.

       

      (b)           Conduct of Indemnification
Proceedings. If any Proceeding shall be brought or asserted against any
person who may be entitled to indemnity pursuant to Section 12(a) hereunder (an
“Indemnified
Party”), such Indemnified Party promptly shall notify the Company (the
“Indemnifying
Party”) in writing, and the Indemnifying Party shall assume the defense
thereof, including the employment of counsel reasonably satisfactory to the
Indemnified Party and the payment of all fees and expenses incurred in
connection with defense thereof; provided, that the
failure of any Indemnified Party to give such notice shall not relieve the
Indemnifying Party of its obligations or liabilities pursuant to this Agreement,
except (and only) to the extent that it shall be finally determined by a court
of competent jurisdiction (which determination is not subject to appeal or
further review) that such failure shall have materially and adversely prejudiced
the Indemnifying Party; provided further,
that the Indemnified Party shall be entitled to assume the defense of the
Proceeding if (i) the Indemnifying Party fails to notify the Indemnified Party
in writing within ten (10) days after the Indemnified Party has given to the
Indemnifying Party the notice required by this Section 12(b) that the
Indemnifying Party will defend the Indemnified Party in the Proceeding and will
indemnify, defend, and hold harmless the Indemnified Party from and against the
Losses related thereto; (ii) the Indemnifying Party fails to provide the
Indemnified Party with reasonable evidence that the Indemnifying Party will have
the financial resources to defend the Indemnified Party in the Proceeding and
fulfill all the Indemnifying Party’s indemnification obligations hereunder;
(iii) the Indemnified Party reasonably concludes that there is a conflict of
interest between the Indemnifying Party and the Indemnified Party in the conduct
of any such defense of the Proceeding; or (iv) the Indemnifying Party fails to
conduct the defense of the Indemnified Party in the Proceeding actively and
diligently.  In the event any of the conditions described in clauses
(i)-(iv) above occur, (A) the Indemnified Party may defend against, consent to
the entry of any judgment or enter into any settlement with respect to the
Proceeding in any manner the Indemnified Party reasonably may deem appropriate
(and the Indemnified Party need not consult with or obtain any consent from the
Indemnifying Party in connection therewith provided that the Indemnified Party
has provided to the Indemnifying Party notice of Indemnified Party’s intent to
defend, consent to entry of judgment or enter into settlement at least two (2)
business days prior thereto); (B) the Indemnifying Party will reimburse the
Indemnified Party promptly and periodically, but in no event later than twenty
(20) days after a 

       

      
        
          
          

        

        
          -8-

          
            

          

        

        
          
          

        

      

       

      written
request for payment therefor first been made by the Indemnified Party, for the
costs of defense of the Proceeding (including reasonable attorneys’ fees and
expenses); and (C) the Indemnifying Party will remain responsible for any
Losses, including damages, attorneys’ fees, costs, judgments, fines and amounts
paid in settlement, that the Indemnified Party may incur resulting from, arising
out of, relating to, in the nature of, or caused by the investigation, defense,
settlement or appeal of the Proceeding to the fullest extent provided in Section
12(a) above.

            

      An
Indemnified Party shall have the right to employ separate counsel in any
Proceeding and to participate in the defense thereof, but the fees and expenses
of such counsel shall be at the expense of such Indemnified Party or Parties
unless: (i) the Indemnifying Party has agreed in writing to pay such fees and
expenses; or (ii) the Indemnifying Party shall have failed promptly to assume
the defense of such Proceeding and to employ counsel reasonably satisfactory to
such Indemnified Party in any such Proceeding; or (iii) any of the conditions
described in clauses (i)-(iv) above occur.  Except as expressly
provided otherwise herein, the Indemnifying Party shall not be liable for any
settlement of any such Proceeding effected without its written consent, which
consent shall not be unreasonably withheld, conditioned or
delayed.  The Indemnifying Party shall not, without the prior written
consent of the Indemnified Party, which consent shall not unreasonably be
withheld, conditioned or delayed, effect any settlement of any pending
Proceeding in respect of which any Indemnified Party is a party, unless such
settlement includes an unconditional release of such Indemnified Party from all
liability on claims that are the subject matter of such Proceeding.

       

      All
reasonable fees and expenses of the Indemnified Party (including reasonable fees
and expenses to the extent incurred in connection with investigating or
preparing to defend a Proceeding in a manner not inconsistent with this Section)
shall be paid to the Indemnified Party, as incurred, within 20 business days of
written notice thereof to the Indemnifying Party (regardless of whether it is
ultimately determined that an Indemnified Party is not entitled to
indemnification hereunder; provided, that the
Indemnifying Party may require such Indemnified Party to undertake to reimburse
all such fees and expenses to the extent it is finally judicially determined
that such Indemnified Party is not entitled to indemnification hereunder or
pursuant to applicable law).

       

       (c)           The
indemnity agreement contained in this Section is in addition to any liability
that the Indemnifying Party may have to the Indemnified Parties.

       

      13.           Other
Purchasers; Best Financial Terms .  Purchaser acknowledges that the Company
intends to seek to enter into other purchase or subscription agreements on terms
substantially similar to the terms of this Agreement with certain other
investors. The Company intends to offer up to an aggregate of 5,200,000 shares
of Common Stock (including those sold to Purchaser and any such other investors)
with a closing date on or before August 8, 2008 (the “Offering”). The Company shall reduce the
Purchase Price per Share provided in this Agreement to match the purchase price
per Share agreed to by any other investors in the Offering if the Company and
such other investors agree to a lower price. In addition, to the extent the
Company provides warrant coverage or any other terms more favorable to any other
investors in the Offering, the Company shall provide Purchaser the same
percentage of warrant coverage (and on the same terms) and such other favorable
terms, if any.

       

      
        
          
          

        

        
          -9-

          
            

          

        

        
          
          

        

      

       

      14.           Miscellaneous.

       

      (a)           Governing
Law.  This Agreement
and all acts and transactions pursuant hereto and the rights and obligations of
the Parties hereto shall be governed, construed and interpreted in accordance
with the laws of the State of California, without giving effect to principles of
conflicts of law. 

       

      (b)           Entire
Agreement; Enforcement of Rights.  This Agreement
sets forth the entire agreement and understanding of the Parties relating to the
subject matter herein and merges all prior discussions between them with regard
to such subject matter.  No modification of or amendment to this
Agreement, nor any waiver of any rights under this Agreement, shall be effective
unless in writing signed by the Parties.  The forbearance in any one
or more instances of a Party to insist upon performance of any of the terms,
covenants or conditions of this Agreement or to exercise any right or privilege
conferred by this Agreement shall not be construed as a waiver of any such
terms, covenants, conditions, rights or privileges, but the same shall continue
and remain in full force and effect as if no such forbearance or waiver had
occurred.  The waiver by a Party of any breach of any of the terms,
covenants or conditions of this Agreement or of any right or privilege conferred
by this Agreement shall not be construed as a subsequent waiver of any such
terms, covenants, conditions, rights or privileges.  No waiver shall
be effective unless it is in writing and signed by an authorized representative
of the waiving Party.

       

      (c)           Severability.  If any provision of
this Agreement or the application thereof is prohibited by law or otherwise
determined to be invalid or unenforceable by a court of competent jurisdiction,
such provision shall be deemed amended to apply to the broadest extent that it
would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity or enforceability of the remaining
provisions of this Agreement so long as this Agreement as so modified continues
to express, without material change, the original intentions of the Parties as
to the subject matter hereof.  The Parties will endeavor in good faith
negotiations to replace the prohibited, invalid or unenforceable provision(s)
with a valid and enforceable provision(s) that will achieve, to the extent
possible, the economic, business and other purposes of the prohibited, invalid
or unenforceable provision(s).

       

      (d)           Construction.  This Agreement is
the result of negotiations between and has been reviewed by the Parties and
their respective counsel, if any; accordingly, this Agreement shall be deemed to
be the product of both of the Parties, and no ambiguity shall be construed in
favor of or against either one of the Parties.

       

      (e)           Survival.  The
representations, warranties, covenants and agreements made in this Agreement
shall survive the closing of the transactions contemplated hereby.

       

      (f)           Notices.  Any notice
required or permitted to given under this Agreement shall be in writing and may
be delivered by hand, by facsimile, or by internationally recognized overnight
private courier.  Except as provided otherwise herein, notices
delivered by hand shall be deemed given upon receipt; notices delivered by
facsimile shall be deemed given upon the sender’s receipt of confirmation of
successful transmission; and notices delivered by internationally recognized
overnight private courier shall be deemed given on the first business day
following deposit with the private courier for overnight
delivery.  All notices shall be addressed as follows:

       

      
        
          
          

        

        
          -10-

          
            

          

        

        
          
          

        

      

       

       

      If to
Purchaser:

       

      Olympus
Corporation

      2-3 Kuboyama-cho,

      Hachioji-shi, Tokyo
192-8512

      Japan

      Attn:  Yasunobu
Toyoshima

      Title:
General Manager

      Facsimile:
+81-42-691-7350

       

      with a
copy (which shall not constitute notice) to:

       

      Squire
Sanders Gaikokuho Kyodo Jigyo Horitsu Jimusho

      Ebisu
Prime Square Tower, 16/F

      1-1-39
Hiroo

      Shibuya-ku,
Tokyo 150-0012

      Japan

      Attention:  Stephen
E. Chelberg, Esq.

      Facsimile:  +81.3.5774.1818

       

      If to the
Company:

       

      Cytori
Therapeutics, Inc.

      3020
Callan Road

      San
Diego, CA 92121

      Attn:
Christopher J. Calhoun

      Facsimile:  858-450-4335

       

      and/or to
such other respective addresses and/or addressees as may be designated by notice
given in accordance with the provisions of this Section 14(f).

       

      (g)           Counterparts.  This Agreement
may be executed in counterparts, each of which shall be deemed an original and
all of which together shall constitute one instrument.

       

      (h)           Facsimile
and E-mail Signatures.  Any signature
page hereto delivered by facsimile machine or by e-mail (including in portable
document format (pdf), as a joint photographic experts group (jpg) file, or
otherwise) shall be binding to the same extent as an original signature page,
with regard to any agreement subject to the terms hereof or any amendment
thereto.  Any Party who delivers such a signature page agrees to later
deliver an original counterpart to any Party who requests it.

       

      (i)           Further
Assurances.  Each Party hereby
covenants that it will, at any time and from time to time upon the reasonable
request by the other Party, execute and deliver such further documents and take
such further actions as the other Party may reasonably request in order to
effect the purposes of this Agreement.

       

       

      [Signature
Page Follows]

       

       

      
        
          
          

        

        
          -11-

          
            

          

        

        
          
          

        

      

       

      The
Parties have executed this Common Stock Purchase Agreement as of the Effective
Date.

       

       

       

      COMPANY:

       

      CYTORI
THERAPEUTICS, INC.

       

      /s/ Christopher J.
Calhoun        

       

      By:  Christopher
J.
Calhoun                                                                      

       

      Title:  Chief
Executive Officer

       

      Date: 
August 7,
2008                                                                      

       

      Address:

      3020
Callan Road

      San
Diego, CA 92121

       

      Fax:  US
858-458-0994

       

      

       

      PURCHASER:

       

      OLYMPUS
CORPORATION

         

      /s/
Tsuyoshi Kikukawa        

       

      By: Tsuyoshi
Kikukawa

       

      Title:
President

       

      Address:

      43-2
Hatagaya 2-chome

      Shibuya-ku,
Tokyo

      Japan

      

      Fax:
Japan 03-3340-2062

      

      

      
        
          
          

        

        
          -12-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]